Background: Circulating tumor cells have been described in prostate cancer patients at diagnosis and in the metastatic phase but little is known on their role at biochemical PSA recurrence. Patients and Methods: Patients radically cured with either prostatectomy or radiotherapy were sequentially included at PSA recurrence. The presence of CTCs was evaluated by the CellSearch system. Results: Twenty-nine patients were accrued at PSA recurrence. Median PSA at recurrence was 7.2 ng/ml (range=3.86-51.0 ng/ml). The median time to PSA progression was 4.66 years (range=0.1-16 years). CTCs were detected in one patient (3%) with low numbers (1 CTC/7.5 ml). Conclusion: In patients radically cured for prostate cancer at biochemical recurrence, CTCs ar...
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor...
AbstractOne of the major challenges that clinicians face is in the difficulties of accurately monito...
High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Tr...
Circulating tumor cells have been described in prostate cancer patients at diagnosis and in the meta...
Prostate cancer is a life-threatening and highly heterogeneous malignancy. In the past decade, circu...
The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and pat...
The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in prostat...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual pati...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective treatmen...
Purpose: The detection of circulating tumor cells (CTCs) provides important prognostic information i...
Background:Following radical prostatectomy, success of adjuvant and salvage radiation therapy (RT) i...
Introduction. Developments in immunological and quantitative real-time PCR-based analysis have enabl...
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor...
AbstractOne of the major challenges that clinicians face is in the difficulties of accurately monito...
High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Tr...
Circulating tumor cells have been described in prostate cancer patients at diagnosis and in the meta...
Prostate cancer is a life-threatening and highly heterogeneous malignancy. In the past decade, circu...
The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and pat...
The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in prostat...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual pati...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective treatmen...
Purpose: The detection of circulating tumor cells (CTCs) provides important prognostic information i...
Background:Following radical prostatectomy, success of adjuvant and salvage radiation therapy (RT) i...
Introduction. Developments in immunological and quantitative real-time PCR-based analysis have enabl...
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor...
AbstractOne of the major challenges that clinicians face is in the difficulties of accurately monito...
High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Tr...